Q-omics provides the consensus-scored BARX1 profile across patient tissues and cancer cell-line models. BARX1 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BARX1 is differentially expressed in 14, with the highest sampling consensus in LUSC. Additionally, BARX1 RNA expression shows 13,139 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LUSC, and LSCC as cancer lineages where BARX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BARX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BARX1 survival associations across molecular data types. BARX1 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BARX1 RNA expression–survival associations across cancer types. High BARX1 expression shows unfavorable associations in KIRC, UVM, UCEC, ACC, MESO and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BARX1 RNA expression.
This table summarizes BARX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BARX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BARX1 shows lower tumor expression in THCA and higher tumor expression in LUSC, LUAD, BLCA, HNSC and BRCA. The LUSC box plot shows higher BARX1 RNA expression in tumor versus normal tissue (log2 FC = +2.986, t-test p < 0.001).
This table shows molecular features associated with BARX1 in patient tissues and cancer cell lines. In patient samples, BARX1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, BARX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LUNG_SCLC.
